Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Reliability, Validity and Usefulness of a New Response Time Test for Agility-Based Sports: A Simple vs. Complex Motor Task.

Authors:
Haris Pojskic Jeffrey Pagaduan Edin Uzicanin Vlatko Separovic Miodrag Spasic Nikola Foretic Damir Sekulic

J Sports Sci Med 2019 12 19;18(4):623-635. Epub 2019 Nov 19.

Faculty of Kinesiology, University of Split, Split, Croatia.

The importance of response time (RT) in sports is well known, but there is an evident lack of reliable and valid sport-specific measurement tools applicable in the evaluation of RT in trained athletes. This study aimed to identify the validity, reliability, and usefulness of four newly developed RT testing protocols among athletes from agility-saturated (AG) and non-agility-saturated (NAG) sports. Thirty-seven AG and ten NAG athletes (age: 20.9 ± 2.9; eleven females) volunteered to undergo: three randomized simple response time (SRT-1, SRT-2, and SRT-3) protocols that included a single limb movement, and one complex response time (CRT) protocol that included multi joint movements and whole body transition over a short distance (1.5 and 1.8m). Each RT test involved 3 trials with 5 randomized attempts per trial. Two sensors were placed at the left- and right-hand side for SRT-1 and SRT-2. Three sensors were positioned (left, middle, right) in SRT-3 and CRT. The intra-class-correlation coefficient (ICC) was calculated as a measure of reliability. Independent sample t-test, effect size (d), and area-under-the-curve (AUC) were calculated to define discriminative validity of the tests. The results showed the newly developed tests were more reliable and useful in the AG than NAG athletes (i.e., ICC between 0.68 and 0.97 versus 0.31-0.90, respectively). The RT of AG athletes was faster than that of NAG athletes in the CRT test from the left (p <0.01, = 2.40, AUC: 0.98), centre (p < 0.01, = 1.57, AUC: 0.89), and right sensor (p < 0.01, = 1.93, AUC: 0.89) locations. In contrast, there were no differences between the groups in the SRT tests. The weak correlation (i.e., r= 0.00-0.33) between the SRT and CRT tests suggests that response time of the single limb and multijoint limb movements should not be considered as a single motor capacity. In conclusion, this study showed that AG athletes had faster response time than their NAG peers during complex motor tasks. Such enhanced ability to rapidly and accurately reprogram complex motor tasks can be considered one of the essential qualities required for advanced performance in agility-based sports.

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873124PMC
December 2019

Publication Analysis

Top Keywords

response time
16
nag athletes
12
srt-1 srt-2
8
newly developed
8
athletes
6
test left
4
females volunteered
4
eleven females
4
positioned left
4
three sensors
4
sensors positioned
4
volunteered undergo
4
209 eleven
4
undergo three
4
srt-2 three
4
three randomized
4
left middle
4
age 209
4
middle srt-3
4
simple response
4

Keyword Occurance

Similar Publications

Predictive capacity of self-rated health on all-cause mortality in Spain: differences across sex, age and educational level.

Authors:
Daniel Suso-Palau Teresa López-Cuadrado Daniela Duque-León Cristina Ortiz Iñaki Galán

J Epidemiol Community Health 2022 Jun 28. Epub 2022 Jun 28.

Department of Preventive Medicine and Public Health, Autonomous University of Madrid, Madrid, Spain

Background: Published evidence on self-rated health's capacity to predict mortality and its variability across subpopulations lacks consistency. Our objective is to evaluate this predictive association and whether/how it varies by sex, age and educational attainment at the population level in Spain.

Methods: Data came from a prospective longitudinal study based on 42 645 individuals aged ≥15 years who participated in the 2011-2012 and 2014 Spanish Health Surveys. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency.

Authors:
Belén de la Morena-Barrio Jonathan Stephens María Eugenia de la Morena-Barrio Luca Stefanucci José Padilla Antonia Miñano Nicholas Gleadall Juan Luis García María Fernanda López-Fernández Pierre-Emmanuel Morange Marja Puurunen Anetta Undas Francisco Vidal Frances Lucy Raymond Vicente Vicente Willem H Ouwehand Javier Corral Alba Sanchis-Juan

Thromb Haemost 2022 Jun 28. Epub 2022 Jun 28.

Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge, United Kingdom.

The identification of inherited antithrombin deficiency (ATD) is critical to prevent potentially life-threatening thrombotic events. Causal variants in are identified for up to 70% of cases, the majority being single-nucleotide variants and indels. The detection and characterization of structural variants (SVs) in ATD remain challenging due to the high number of repetitive elements in . Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Authors:
T André S Lonardi K Y M Wong H-J Lenz F Gelsomino M Aglietta M A Morse E Van Cutsem R McDermott A Hill M B Sawyer A Hendlisz B Neyns S Abdullaev A Memaj M Lei M Dixon S Kopetz M J Overman

Ann Oncol 2022 Jun 25. Epub 2022 Jun 25.

Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Background: In the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety profile in previously treated patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) at 13.4- and 25.4-month median follow-up (Overman M et al. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

A Self-amplifying ROS-sensitive prodrug-based nanodecoy for circumventing immune resistance in chemotherapy-sensitized immunotherapy.

Authors:
Jiulong Zhang Xiaoyan Sun Mengdan Xu Xiufeng Zhao Chunrong Yang Kexin Li Fan Zhao Haiyang Hu Mingxi Qiao Dawei Chen Xiuli Zhao

Acta Biomater 2022 Jun 25. Epub 2022 Jun 25.

School of Pharmacy, Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang, 110016, P.R. China. Electronic address:

Circumventing immune resistance and boosting immune response is the ultimate goal of cancer immunotherapy. Herein, we reported a tumor-associated macrophage (TAM) membrane-camouflaged nanodecoy containing a self-amplifying reactive oxygen species (ROS)-sensitive prodrug nanoparticle for specifically inducing immunogenic cell death (ICD) in combination with TAM depletion. A versatile ROS-cleavable camptothecin (CPT) prodrug (DCC) was synthesized through a thioacetal linker between CPT and the ROS generator cinnamaldehyde (CA), which could self-assemble into a uniform prodrug nanoparticle to realize a positive feedback loop of "ROS-triggered CA/CPT release and CA/CPT-mediated ROS generation. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer.

Authors:
Aileen I Fernandez Niki Gavrielatou Leena McCann Saba Shafi Myrto K Moutafi Sandra Martinez-Morilla Ioannis A Vathiotis Thazin Nwe Aung Vesal Yaghoobi Yalai Bai Yvonne G Chan Jodi Weidler Roy Herbst Michael Bates David L Rimm

J Thorac Oncol 2022 Jun 25. Epub 2022 Jun 25.

Department of Pathology, Yale University School of Medicine, New Haven, CT; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT. Electronic address:

Introduction: Immune checkpoint inhibitors (ICIs) have become standard of care in lung cancer management, but only a relatively small percentage of patients treated respond. Current predictive biomarkers, including immunohistochemical (IHC) detection of PD-L1, are insufficient for determining who will respond or, more importantly in the adjuvant setting, who will not respond to ICI therapy. Here, we investigate an alternative method of assessment of PD-L1 to predict non-response. Read More

View Article and Full-Text PDF
June 2022
Similar Publications
}